NAVB logo

NAVB EBITDA

Annual EBITDA

-$14.05 M
-$2.42 M-20.80%

December 31, 2022


Summary


Performance

NAVB EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherNAVBprofitabilitymetrics:

Quarterly EBITDA

-$2.10 M
+$296.30 K+12.34%

September 30, 2023


Summary


Performance

NAVB Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherNAVBprofitabilitymetrics:

TTM EBITDA

-$8.89 M
+$2.82 M+24.09%

September 30, 2023


Summary


Performance

NAVB TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherNAVBprofitabilitymetrics:

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

NAVB EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-20.8%+12.3%+24.1%
3 y3 years-29.9%+12.3%+24.1%
5 y5 years-3.1%+12.3%+24.1%

NAVB EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-20.8%at low-77.5%+57.3%at high+36.7%
5 y5-year-32.0%at low-77.5%+57.3%at high+36.7%
alltimeall time-789.3%+74.7%-400.0%+93.9%-585.6%+77.5%

Navidea Biopharmaceuticals EBITDA History

DateAnnualQuarterlyTTM
Sep 2023
-
-$2.10 M(-12.3%)
-$8.89 M(-24.1%)
Jun 2023
-
-$2.40 M(+102.5%)
-$11.71 M(-4.1%)
Mar 2023
-
-$1.19 M(-62.9%)
-$12.21 M(-12.7%)
Dec 2022
-$14.05 M(+20.8%)
-$3.20 M(-35.0%)
-$13.99 M(-0.5%)
Sep 2022
-
-$4.93 M(+69.8%)
-$14.05 M(+21.9%)
Jun 2022
-
-$2.90 M(-2.0%)
-$11.53 M(+2.2%)
Mar 2022
-
-$2.96 M(-9.4%)
-$11.28 M(+0.1%)
Dec 2021
-$11.63 M(+9.3%)
-$3.27 M(+35.9%)
-$11.27 M(+4.5%)
Sep 2021
-
-$2.40 M(-9.3%)
-$10.78 M(-4.3%)
Jun 2021
-
-$2.65 M(-10.1%)
-$11.26 M(+3.0%)
Mar 2021
-
-$2.95 M(+5.9%)
-$10.93 M(+2.7%)
Dec 2020
-$10.64 M(-1.6%)
-$2.78 M(-3.5%)
-$10.64 M(+0.4%)
Sep 2020
-
-$2.88 M(+24.2%)
-$10.59 M(-1.6%)
Jun 2020
-
-$2.32 M(-12.5%)
-$10.76 M(-2.8%)
Mar 2020
-
-$2.65 M(-3.0%)
-$11.08 M(+2.4%)
Dec 2019
-$10.82 M(+1.1%)
-$2.74 M(-10.3%)
-$10.82 M(+5.6%)
Sep 2019
-
-$3.05 M(+15.7%)
-$10.25 M(-5.8%)
Jun 2019
-
-$2.64 M(+10.0%)
-$10.88 M(+2.3%)
Mar 2019
-
-$2.40 M(+10.7%)
-$10.63 M(-0.6%)
Dec 2018
-$10.70 M(-21.5%)
-$2.16 M(-41.2%)
-$10.70 M(-10.9%)
Sep 2018
-
-$3.68 M(+54.3%)
-$12.01 M(+12.6%)
Jun 2018
-
-$2.39 M(-3.0%)
-$10.66 M(-18.1%)
Mar 2018
-
-$2.46 M(-29.2%)
-$13.02 M(-4.4%)
Dec 2017
-$13.62 M(+41.2%)
-$3.48 M(+48.9%)
-$13.62 M(+2.7%)
Sep 2017
-
-$2.34 M(-50.8%)
-$13.26 M(+13.1%)
Jun 2017
-
-$4.75 M(+55.1%)
-$11.73 M(+28.9%)
Mar 2017
-
-$3.06 M(-1.8%)
-$9.10 M(-5.7%)
Dec 2016
-$9.65 M(-46.0%)
-$3.12 M(+290.5%)
-$9.65 M(+8.6%)
Sep 2016
-
-$798.30 K(-62.4%)
-$8.88 M(-27.6%)
Jun 2016
-
-$2.12 M(-41.2%)
-$12.27 M(-11.1%)
Mar 2016
-
-$3.61 M(+53.5%)
-$13.81 M(-22.7%)
Dec 2015
-$17.87 M(-34.1%)
-$2.35 M(-43.9%)
-$17.87 M(-10.0%)
Sep 2015
-
-$4.19 M(+14.5%)
-$19.85 M(-5.0%)
Jun 2015
-
-$3.66 M(-52.2%)
-$20.90 M(-20.6%)
Mar 2015
-
-$7.67 M(+76.8%)
-$26.33 M(-3.0%)
Dec 2014
-$27.13 M(-28.7%)
-$4.34 M(-17.2%)
-$27.13 M(-20.2%)
Sep 2014
-
-$5.24 M(-42.4%)
-$34.01 M(-12.8%)
Jun 2014
-
-$9.09 M(+7.4%)
-$39.02 M(-1.5%)
Mar 2014
-
-$8.47 M(-24.5%)
-$39.60 M(+4.1%)
Dec 2013
-$38.03 M(+36.9%)
-$11.21 M(+9.4%)
-$38.03 M(+12.7%)
Sep 2013
-
-$10.24 M(+5.9%)
-$33.76 M(+4.7%)
Jun 2013
-
-$9.68 M(+40.2%)
-$32.25 M(+15.0%)
Mar 2013
-
-$6.90 M(-0.5%)
-$28.03 M(+0.9%)
Dec 2012
-$27.79 M(+11.8%)
-$6.94 M(-20.5%)
-$27.79 M(-6.9%)
Sep 2012
-
-$8.73 M(+59.9%)
-$29.85 M(+8.4%)
Jun 2012
-
-$5.46 M(-18.0%)
-$27.54 M(+7.5%)
Mar 2012
-
-$6.66 M(-26.0%)
-$25.63 M(+3.1%)
Dec 2011
-$24.86 M(-55.2%)
-$9.00 M(+40.2%)
-$24.86 M(+27.4%)
Sep 2011
-
-$6.42 M(+81.1%)
-$19.51 M(+16.5%)
Jun 2011
-
-$3.54 M(-39.8%)
-$16.74 M(+18.9%)
Mar 2011
-
-$5.89 M(+61.4%)
-$14.08 M(+42.8%)
Dec 2010
-$55.47 M(+3619.5%)
-$3.65 M(-0.1%)
-$9.86 M(+49.9%)
Sep 2010
-
-$3.65 M(+316.0%)
-$6.58 M(+107.7%)
Jun 2010
-
-$878.50 K(-47.5%)
-$3.17 M(+3.4%)
Mar 2010
-
-$1.67 M(+351.6%)
-$3.06 M(+105.4%)
Dec 2009
-$1.49 M(-29.0%)
-$370.70 K(+52.1%)
-$1.49 M(+20.6%)
Sep 2009
-
-$243.80 K(-68.5%)
-$1.24 M(-50.7%)
Jun 2009
-
-$774.20 K(+655.3%)
-$2.51 M(+43.3%)
Mar 2009
-
-$102.50 K(-11.3%)
-$1.75 M(-6.3%)
Dec 2008
-$2.10 M
-$115.60 K(-92.4%)
-$1.87 M(-94.8%)
Sep 2008
-
-$1.52 M(+8925.0%)
-$36.05 M(+4.1%)
Jun 2008
-
-$16.80 K(-92.4%)
-$34.62 M(-1.1%)
DateAnnualQuarterlyTTM
Mar 2008
-
-$220.50 K(-99.4%)
-$34.99 M(-0.4%)
Dec 2007
-$35.48 M(+1484.2%)
-$34.30 M(>+9900.0%)
-$35.15 M(+2321.6%)
Sep 2007
-
-$90.00 K(-76.7%)
-$1.45 M(-39.2%)
Jun 2007
-
-$385.90 K(+2.6%)
-$2.39 M(+5.2%)
Mar 2007
-
-$376.10 K(-37.3%)
-$2.27 M(+1.4%)
Dec 2006
-$2.24 M(-4.8%)
-$599.50 K(-41.6%)
-$2.24 M(-3.3%)
Sep 2006
-
-$1.03 M(+281.9%)
-$2.32 M(+18.7%)
Jun 2006
-
-$268.80 K(-22.1%)
-$1.95 M(-19.9%)
Mar 2006
-
-$345.00 K(-49.0%)
-$2.44 M(+3.6%)
Dec 2005
-$2.35 M(+105.9%)
-$677.00 K(+2.3%)
-$2.35 M(+3.6%)
Sep 2005
-
-$661.70 K(-12.2%)
-$2.27 M(+39.4%)
Jun 2005
-
-$753.60 K(+189.0%)
-$1.63 M(+48.4%)
Mar 2005
-
-$260.80 K(-56.2%)
-$1.10 M(-3.9%)
Dec 2004
-$1.14 M(+34.0%)
-$596.00 K(+2956.4%)
-$1.14 M(+23.8%)
Sep 2004
-
-$19.50 K(-91.2%)
-$923.70 K(-27.6%)
Jun 2004
-
-$222.20 K(-27.2%)
-$1.28 M(+41.4%)
Mar 2004
-
-$305.40 K(-18.9%)
-$901.90 K(+5.7%)
Dec 2003
-$853.30 K(-61.6%)
-$376.60 K(+1.5%)
-$853.30 K(+38.4%)
Sep 2003
-
-$371.00 K(-345.5%)
-$616.40 K(-41.6%)
Jun 2003
-
$151.10 K(-158.8%)
-$1.06 M(-43.9%)
Mar 2003
-
-$256.80 K(+83.8%)
-$1.88 M(-15.4%)
Dec 2002
-$2.22 M(-332.8%)
-$139.70 K(-82.8%)
-$2.22 M(+27.2%)
Sep 2002
-
-$809.90 K(+19.8%)
-$1.75 M(+152.6%)
Jun 2002
-
-$676.00 K(+12.9%)
-$692.50 K(-404.3%)
Mar 2002
-
-$598.90 K(-278.5%)
$227.60 K(-76.2%)
Dec 2001
$955.60 K(-53.1%)
$335.50 K(+35.9%)
$956.40 K(-27.7%)
Sep 2001
-
$246.90 K(+1.1%)
$1.32 M(-12.4%)
Jun 2001
-
$244.10 K(+87.9%)
$1.51 M(-17.5%)
Mar 2001
-
$129.90 K(-81.5%)
$1.83 M(+11.2%)
Dec 2000
$2.04 M(-150.6%)
$701.40 K(+61.5%)
$1.65 M(+74.3%)
Sep 2000
-
$434.30 K(-23.2%)
$944.50 K(+85.1%)
Jun 2000
-
$565.30 K(-1126.0%)
$510.20 K(-144.2%)
Mar 2000
-
-$55.10 K(-95.0%)
-$1.16 M(-93.7%)
Dec 1999
-$4.03 M(-85.2%)
-
-
Jun 1999
-
-$1.10 M(-21.4%)
-$18.27 M(-16.1%)
Mar 1999
-
-$1.40 M(-88.3%)
-$21.77 M(-21.3%)
Dec 1998
-$27.20 M(+3.1%)
-$11.97 M(+215.0%)
-$27.67 M(+14.5%)
Sep 1998
-
-$3.80 M(-17.4%)
-$24.16 M(-6.9%)
Jun 1998
-
-$4.60 M(-37.0%)
-$25.96 M(-10.7%)
Mar 1998
-
-$7.30 M(-13.8%)
-$29.06 M(+7.0%)
Dec 1997
-$26.37 M(+16.2%)
-$8.46 M(+51.2%)
-$27.16 M(+3.7%)
Sep 1997
-
-$5.60 M(-27.3%)
-$26.20 M(-4.0%)
Jun 1997
-
-$7.70 M(+42.6%)
-$27.30 M(+10.1%)
Mar 1997
-
-$5.40 M(-28.0%)
-$24.80 M(+6.4%)
Dec 1996
-$22.70 M(+108.3%)
-$7.50 M(+11.9%)
-$23.30 M(+22.6%)
Sep 1996
-
-$6.70 M(+28.8%)
-$19.00 M(+25.8%)
Jun 1996
-
-$5.20 M(+33.3%)
-$15.10 M(+20.8%)
Mar 1996
-
-$3.90 M(+21.9%)
-$12.50 M(+9.6%)
Dec 1995
-$10.90 M(-2.7%)
-$3.20 M(+14.3%)
-$11.40 M(-5.0%)
Sep 1995
-
-$2.80 M(+7.7%)
-$12.00 M(0.0%)
Jun 1995
-
-$2.60 M(-7.1%)
-$12.00 M(+5.3%)
Mar 1995
-
-$2.80 M(-26.3%)
-$11.40 M(+2.7%)
Dec 1994
-$11.20 M(+38.3%)
-$3.80 M(+35.7%)
-$11.10 M(+13.3%)
Sep 1994
-
-$2.80 M(+40.0%)
-$9.80 M(+6.5%)
Jun 1994
-
-$2.00 M(-20.0%)
-$9.20 M(0.0%)
Mar 1994
-
-$2.50 M(0.0%)
-$9.20 M(+15.0%)
Dec 1993
-$8.10 M(+179.3%)
-$2.50 M(+13.6%)
-$8.00 M(+19.4%)
Sep 1993
-
-$2.20 M(+10.0%)
-$6.70 M(+26.4%)
Jun 1993
-
-$2.00 M(+53.8%)
-$5.30 M(+60.6%)
Mar 1993
-
-$1.30 M(+8.3%)
-$3.30 M(+65.0%)
Dec 1992
-$2.90 M
-$1.20 M(+50.0%)
-$2.00 M(+150.0%)
Sep 1992
-
-$800.00 K
-$800.00 K

FAQ

  • What is Navidea Biopharmaceuticals annual EBITDA?
  • What is the all time high annual EBITDA for Navidea Biopharmaceuticals?
  • What is Navidea Biopharmaceuticals annual EBITDA year-on-year change?
  • What is Navidea Biopharmaceuticals quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Navidea Biopharmaceuticals?
  • What is Navidea Biopharmaceuticals quarterly EBITDA year-on-year change?
  • What is Navidea Biopharmaceuticals TTM EBITDA?
  • What is the all time high TTM EBITDA for Navidea Biopharmaceuticals?
  • What is Navidea Biopharmaceuticals TTM EBITDA year-on-year change?

What is Navidea Biopharmaceuticals annual EBITDA?

The current annual EBITDA of NAVB is -$14.05 M

What is the all time high annual EBITDA for Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals all-time high annual EBITDA is $2.04 M

What is Navidea Biopharmaceuticals annual EBITDA year-on-year change?

Over the past year, NAVB annual EBITDA has changed by -$2.42 M (-20.80%)

What is Navidea Biopharmaceuticals quarterly EBITDA?

The current quarterly EBITDA of NAVB is -$2.10 M

What is the all time high quarterly EBITDA for Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals all-time high quarterly EBITDA is $701.40 K

What is Navidea Biopharmaceuticals quarterly EBITDA year-on-year change?

Over the past year, NAVB quarterly EBITDA has changed by +$296.30 K (+12.34%)

What is Navidea Biopharmaceuticals TTM EBITDA?

The current TTM EBITDA of NAVB is -$8.89 M

What is the all time high TTM EBITDA for Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals all-time high TTM EBITDA is $1.83 M

What is Navidea Biopharmaceuticals TTM EBITDA year-on-year change?

Over the past year, NAVB TTM EBITDA has changed by +$2.82 M (+24.09%)